Delayed contact hypersensitivity to non-steroidal anti-inflammatory drugs

被引:20
作者
Gniazdowska, B [1 ]
Ruëff, F [1 ]
Przybilla, B [1 ]
机构
[1] Univ Munich, Klinikum Innenstadt, Klin & Poliklin Dermatol & Allergol, D-80337 Munich, Germany
关键词
bufexamac; allergic contact dermatitis; etofenamate; flufenamic acid; indomethacin; non-steroidal anti-inflammatory drugs; medicaments;
D O I
10.1111/j.1600-0536.1999.tb05992.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Several non-steroidal anti-inflammatory drugs (NSAIDs) are available for topical treatment of acute soft tissue trauma or degenerative musculoskeletal disorders; the NSAID bufexamac is mainly used for therapy of chronic inflammatory skin diseases. In order to assess the occurrence of contact allergy to NSAIDs in 371 consecutive patients presenting for diagnosis of presumed contact allergy, patch tests were performed with a standard series and additionally with a series of NSAIDs, comprising acetylsalicylic acid, bufexamac, diclofenac, etofenamate, felbinac, flufenamic acid, ibuprofen, indomethacin, and piroxicam. 17 individuals (4.6%) exhibited delayed hypersensitivity to one of the NSAID preparations: 12 patients (3.2%) had patch test reactions to bufexamac, 2 (0.5%) to etofenamate, 2 (0.5%) to indomethacin, and 1 patient (0.3%) to flufenamic acid. These patch test results corresponded well to the individual history in 11 individuals (including 10 patients with reactions to bufexamac), and in 2 patients the clinical relevance of the reactions was probable. In view of the high frequency of allergic contact reactions to bufexamac, we propose to test this drug particularly in patients with atopic eczema or other chronic eczematous diseases.
引用
收藏
页码:63 / 65
页数:3
相关论文
共 14 条
  • [1] AERTGEERTS P, 1985, Z HAUTKRANKHEITEN, V60, P270
  • [2] BOLTEN W, 1989, Z RHEUMATOL, V48, P317
  • [3] *BUND PHARM IND, 1997, ROT LIST 1997
  • [4] FROSCH PJ, 1987, HAUTARZT, V38, P331
  • [5] Frosch PJ, 1987, Z HAUTKRANKHEITEN, V23, P1631
  • [6] ERYTHEMA-MULTIFORME-LIKE, URTICARIAL PAPULAR AND PLAQUE ERUPTIONS FROM BUFEXAMAC - REPORT OF 4 CASES
    KOCH, P
    BAHMER, FA
    [J]. CONTACT DERMATITIS, 1994, 31 (02) : 97 - 101
  • [7] Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer
    Kranke, B
    SzolarPlatzer, C
    Komericki, P
    Derhaschnig, J
    Aberer, W
    [J]. CONTACT DERMATITIS, 1997, 36 (04) : 212 - 215
  • [8] MOZZANICA N, 1989, CURRENT TOPICS CONTA, P499
  • [9] TOPICAL NSAID ALLERGIC CONTACT-DERMATITIS ITALIAN EXPERIENCE
    PIGATTO, PD
    MOZZANICA, N
    BIGARDI, AS
    LEGORI, A
    VALSECCHI, R
    CUSANO, F
    TOSTI, A
    GUARRERA, M
    BALATO, N
    SERTOLI, A
    [J]. CONTACT DERMATITIS, 1993, 29 (01) : 39 - 41
  • [10] PIGATTO PD, 1995, CONTACT DERMATITIS, V12, P236